Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects.

@article{VidalTorres2013Sigma1RA,
  title={Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects.},
  author={Alba Vidal-Torres and Beatriz de la Puente and Maria Rocasalbas and Clara Touri{\~n}o and Simona Andreea Bura and Bego{\~n}a Fern{\'a}ndez-Pastor and L. Enrique Romero and Xavier Codony and Daniel Zamanillo and Helmut Buschmann and Manuel Merlos and Jos{\'e} Manuel Baeyens and Rafael Maldonado and Jos{\'e} Miguel Vela},
  journal={European journal of pharmacology},
  year={2013},
  volume={711 1-3},
  pages={63-72}
}
While opioids are potent analgesics widely used in the management of pain, a number of well-known adverse effects limit their use. The sigma-1 receptor is a ligand-regulated molecular chaperone involved in pain processing, including modulation of opioid antinociception. However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands. Also, safety issues derived from combination therapy are poorly addressed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Sigma receptors [σRs]: biology in normal and diseased states

Journal of receptor and signal transduction research • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…